[{"id":"9f749ec0-9a4e-415b-87ef-80069ba67c42","acronym":"MA-CRC-II-018","url":"https://clinicaltrials.gov/study/NCT07478731","created_at":"2026-03-28T01:41:18.497Z","updated_at":"2026-03-28T01:41:18.497Z","phase":"Phase 2","brief_title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT07478731 - MA-CRC-II-018","lead_sponsor":"Hong Qiu","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/20/2025","start_date":" 12/20/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-17"},{"id":"fae12559-05ff-4175-9322-233f03620f30","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159828","created_at":"2025-09-13T08:45:52.032Z","updated_at":"2025-09-13T08:45:52.032Z","phase":"Phase 1","brief_title":"A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07159828","lead_sponsor":"Instil Bio","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-09-08"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"0dede7b9-ee1b-410d-9416-c7e60518928b","acronym":"NSGO","url":"https://clinicaltrials.gov/study/NCT03267589","created_at":"2025-08-02T14:05:36.136Z","updated_at":"2025-08-02T14:05:36.136Z","phase":"Phase 2","brief_title":"Trial in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03267589 - NSGO","lead_sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","biomarkers":" CD73","pipe":"","alterations":" ","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2021","study_completion_date":" 10/19/2021","last_update_posted":"2025-07-29"},{"id":"5e1e2228-b845-457c-bca6-09f91e2f7839","acronym":"","url":"https://clinicaltrials.gov/study/NCT07049848","created_at":"2025-07-05T13:58:03.171Z","updated_at":"2025-07-05T13:58:03.171Z","phase":"Phase 2","brief_title":"SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma","source_id_and_acronym":"NCT07049848","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • doxorubicin hydrochloride"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-07-03"},{"id":"ddd7f583-bad9-403a-9835-38c48d3a337c","acronym":"DARTS","url":"https://clinicaltrials.gov/study/NCT07027436","created_at":"2025-06-21T13:17:48.762Z","updated_at":"2025-06-21T13:17:48.762Z","phase":"Phase 3","brief_title":"Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","source_id_and_acronym":"NCT07027436 - DARTS","lead_sponsor":"Hamilton Health Sciences Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2025","start_date":" 07/07/2025","primary_txt":" Primary completion: 10/12/2027","primary_completion_date":" 10/12/2027","study_txt":" Completion: 10/10/2028","study_completion_date":" 10/10/2028","last_update_posted":"2025-06-18"},{"id":"5de3ae22-f200-40ed-bea2-6427c55b3ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984328","created_at":"2025-06-07T14:42:38.975Z","updated_at":"2025-06-07T14:42:38.975Z","phase":"Phase 2","brief_title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","source_id_and_acronym":"NCT06984328","lead_sponsor":"Genmab","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2029","study_completion_date":" 07/15/2029","last_update_posted":"2025-06-03"},{"id":"16167a12-edc3-4776-9942-2975c9714e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03258593","created_at":"2025-06-07T14:49:21.304Z","updated_at":"2025-06-07T14:49:21.304Z","phase":"Phase 1","brief_title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","source_id_and_acronym":"NCT03258593","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vicineum (oportuzumab monatox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2025-05-30"},{"id":"0e3b7313-f974-4ff1-8e45-f190a050cd4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06959693","created_at":"2025-09-07T01:30:19.058Z","updated_at":"2025-09-07T01:30:19.058Z","phase":"Phase 2/3","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT06959693","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-05-06"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"0e9bd26b-0254-4ab8-9cad-e1d2a53d9952","acronym":"PRESERVE-003","url":"https://clinicaltrials.gov/study/NCT05671510","created_at":"2023-01-04T14:58:53.390Z","updated_at":"2025-02-25T12:38:29.772Z","phase":"Phase 3","brief_title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05671510 - PRESERVE-003","lead_sponsor":"OncoC4, Inc.","biomarkers":" LAG3 • CTLA4 • TIGIT","pipe":"","alterations":" ","tags":["LAG3 • CTLA4 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • gotistobart (BNT316)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"65d9c2cb-0676-43e5-831c-bcc76a373ee1","acronym":"RESOLVE","url":"https://clinicaltrials.gov/study/NCT05154994","created_at":"2021-12-13T14:12:40.514Z","updated_at":"2025-02-25T12:38:04.917Z","phase":"Phase 1","brief_title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma","source_id_and_acronym":"NCT05154994 - RESOLVE","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":"","alterations":" ","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-24"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"898413db-97d2-4355-9135-1c43e6af96ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458922","created_at":"2021-01-18T21:26:29.307Z","updated_at":"2025-02-25T12:37:37.197Z","phase":"Phase 2","brief_title":"Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma","source_id_and_acronym":"NCT04458922","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EWSR1 • ATF1 • CREB1","pipe":"","alterations":" ","tags":["EWSR1 • ATF1 • CREB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 12/13/2025","study_completion_date":" 12/13/2025","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"4cfc5715-dc42-47d6-8b29-f4162141b070","acronym":"20-C-0012","url":"https://clinicaltrials.gov/study/NCT04235777","created_at":"2021-01-29T07:20:15.829Z","updated_at":"2025-02-25T13:40:02.108Z","phase":"Phase 1","brief_title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","source_id_and_acronym":"NCT04235777 - 20-C-0012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-21"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"e9e77af0-89f1-42d4-a03f-cc0813b452ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027086","created_at":"2023-09-07T16:09:42.798Z","updated_at":"2025-02-25T13:41:42.827Z","phase":"Phase 1/2","brief_title":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","source_id_and_acronym":"NCT06027086","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • sirpiglenastat (DRP-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2025-02-21"},{"id":"4405fdfb-3952-4954-a472-701ca7d88a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821777","created_at":"2023-04-20T14:03:54.395Z","updated_at":"2025-02-25T13:49:46.186Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05821777","lead_sponsor":"Centessa Pharmaceuticals (UK) Limited","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itanistomig (LB101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/05/2027","study_completion_date":" 01/05/2027","last_update_posted":"2025-02-20"}]